このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

第 2 相、ウェルナー症候群におけるプロゲリニンの安全性と忍容性を評価する非盲検試験

2026年9月30日 更新者:PRG Science & Technology Co., Ltd.

典型的なウェルナー症候群の被験者の骨密度 (BMD) 損失の治療におけるプロゲリニンの安全性と忍容性を評価する第 2 相非盲検試験

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

調査の概要

状態

募集

介入・治療

詳細な説明

Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.

To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.

The secondary objectives of this study are:

  • To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
  • To evaluate vascular function in subjects with typical Werner Syndrome.
  • To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
  • To evaluate lipid metabolism in subjects with typical Werner Syndrome.
  • To evaluate physical function in subjects with typical Werner Syndrome.
  • To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.

研究の種類

介入

入学 (推定)

5

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • 募集
        • University of Michigan

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

[Inclusion Criteria]

  1. Subjects must be at least ≥ 18 years of age.

  2. Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.

  3. Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.

  4. Male or non-pregnant, non-lactating female.

  5. Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.

  6. Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.

    Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.

  7. Provide signed written informed consent and willingness, ability to comply with study requirements.

  8. Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.

[Exclusion Criteria]

  1. Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:

    • Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
    • Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
    • Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
  2. Subjects with significant dehydration as judged by the principal investigator.

  3. Subjects with pericardial fluid, ascites and pleural effusion.

  4. Therapy with investigational drugs within 30 days of beginning study medication.

  5. History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.

  6. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.

  7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).

  8. Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).

  9. Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.

  10. Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).

  11. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.

  12. Pregnant or lactating women.

  13. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.

  14. Inability to return for scheduled treatment and assessments.

  15. Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment Group

all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year

This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
時間枠:Baseline to Week 56 (including 4-week follow-up)

The intensity of the event will be graded using CTCAE v6.0 criteria

Baseline to Week 56 (including 4-week follow-up)
Incidence of Treatment-Related Adverse Events
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of Serious Adverse Events (SAEs)
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of TEAEs and SAEs leading to discontinuation of study medication
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Blood Chemistry from Baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Hematology from Baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Urinalysis Results from Baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Height (cm) from Baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Weight (kg) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Temperature (°C) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Pulse Rate (beats per minute) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Respiratory Rate (breaths per minute) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Systolic Blood pressure (mmHg) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Diastolic Blood pressure (mmHg) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Physical Examination findings from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG Ventricular Rate (beats per minute) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG PR interval (msec) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QRS interval (msec) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QT interval (msec) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QTc interval (msec) from baseline
時間枠:Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)

二次結果の測定

結果測定
時間枠
Change in Femur Bone Mineral Density (BMD) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lumbar Spine BMD from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Aortic Pulse Wave Velocity (m/s) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lipid Profile from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Handgrip Strength Test from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Osteocalcin (OC) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Procollagen Peptides (P1NP) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Deoxypyridinium (DPD) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
時間枠:Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
時間枠:Baseline, Week12, Week 24, Week 36 and Week 52
Baseline, Week12, Week 24, Week 36 and Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2023年3月31日

QC基準を満たした最初の提出物

2023年4月26日

最初の投稿 (実際)

2023年5月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する